RAD51 and XRCC3 Gene Polymorphisms and the Risk of Developing Acute Myeloid Leukemia

Abstract

RAD51 (Rec A homolog of E.coli) is a polymorphic gene and one of the central proteins in homologous recombination-DNA-double-stand breaks (HR-DNA-DSB) repair pathway, which is vital in maintaining genetic stability within a cell. The x-ray repair cross complementing (XRCC3) protein also functions in HR-DNA-DSB repair pathway and directly interacts with and stabilizes RAD51 and the closely related RAD51C. The aim of this study was to determine the prevalence of the RAD51 and XRCC3 repair gene polymorphisms among acute myeloid leukemia (AML) patients and to define their role in development of AML and its correlation with the clinical presentation, laboratory data as well as treatment outcome using polymerase chain reaction-restriction fragment length polymorphism assay in 50 de novo AML patients as well as 30 healthy subjects as a control group. Our study revealed that RAD51 G135C and XRCC3 Thr241Met alleles were associated with increased risk of AML with odds ratio (OR) of 2.833 and 2.909 and 95% confidence interval (CI) of 1.527 to 8.983 and 1.761 to 9.788, respectively. Moreover, when combining the 2 genes polymorphisms, a significant elevation of the risk of AML was found with OR of 3.124 and 95% CI of 1.872 to 11.243. As regards treatment outcome, a highly statistical significant difference was found between XRCC3 genotypes with P value of 0.001, whereas no significant difference was present between RAD51 genotypes with P value of 0.29. This clarifies that XRCC3 gene polymorphisms was found to have a significant impact on the risk of treatment failure with OR of 3.560 and 95% CI of 1.167 to 10.875; however, RAD51 gene polymorphism was not found to have an equivalent effect with OR of 2.813 and 95% CI of 0.933 to 10.828. So XRCC3 gene polymorphism might be considered as a prognostic marker in AML. In conclusion, RAD51 and XRCC3 genes polymorphisms may play an important role in the development of AML.

Keywords

PCR-RFLP AML

Get full access to this article

View all access options for this article.

References

Estey

EH.

Prognostic factors in acute myelogenous leukemia. Leukemia. 2001;15(4):670–672.

Schnittger

, Schoch

, Duges

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2005;100:59–66.

De Boer

JG.

Polymorphisms in DNA repair and environmental interactions. Mutat Res. 2002;100:3761–3765.

Jackson

Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23(5):687–696.

Seedhouse

, Faulkner

, Ashraf

, . Polymorphisms in genes involved in homologous recombination repair interacts to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10:2675–2680.

Kurumizaka

, Ikawa

, Nakada

, . Homologous-pairing activity of the human DNA-repair proteins XRCC3 and RAD51C. Proc Natl Acad Sci USA. 2001;98:5538–5543.

Brenneman

, Wagener

, Miller

XRCC 3 controls the fidelity of homologous recombination: roles for XRCC3 in late stages of recombination. Mol Cell. 2002;10:387–395.

Celkan

, Guven

, Batar

, . The difference between pre-B cell acute lymphoblastic leukemia and Burkitt lymphoma in relation to DNA damage repair gene polymorphisms in childhood. Leuk Lymphoma. 2008;49:1638–1640.

Pedersen-Bjergaard

, Andersen

, Christiansen

, . Genetic pathways in therapy-related myelodysplasia and myeloid leukemia. Blood. 2002;99:1909–1912.

10.

Seedhouse

, Bainton

, Lewis

, . The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100:3761–3766.

11.

Jiao

, Hassan

, Bondy

, . XRCC2 and XRCC3 Gene Polymorphism and risk of pancreatic cancer. Am J Gastroenterol. 2008;103(2):360–367.

12.

Thacker

The RAD51 gene family, genetic instability and cancer. Cancer Res. 2005;219(2):125–135.

13.

Voso

, Fabiani

, Alo

, . Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol. 2007;18(9):1523–1528.

14.

Vogel

XRCC 3 (X-ray repair complementing defective repair in Chinese hamster cells 3). Genet Oncol Haematol. 2005;163:38–43.

15.

Pakakasama

, Griffin

, Thaker

XRCC is required in genetic stability, embryonic neurogenesis and viability in mice. Embo J. 2007;19:6675–6685.

16.

Jawad

, Seedhouse

, Russell

, . Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood. 2006;108(12):3916–3918.

17.

Rollinson

, Alexandra

, Smith

, . BottRAD 51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leukemia Res. 2007;31(2):169–174.

18.

Davis

, Masson

, Mcllwraith

Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell. 2001;7:273–282.

19.

Yin

, Vogel

, Ma

, . The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;10:112–120.

20.

Bhatla

, Gerbing

, Alonzo

DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008;22(2):265–272.

21.

Liu

, Yang

, Zhang

, . Polymorphisms of RAD51 (G135C) and XRCC3 (C241T) genes and correlations there of with prognosis and clinical outcomes of acute myeloid leukemia. Mol Cell. 2008;88(6):378–382.

22.

Bolufer

, Collado

, Barragán

, . The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007;92(3):308–314.